NCT05996523View on ClinicalTrials.gov

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

May 22, 2025

Study Completion Date

July 16, 2030

Conditions
Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
BIOLOGICAL

PRGN-2009

PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart

DRUG

Pembrolizumab

Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT05996523 - Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer | Biotech Hunter | Biotech Hunter